After scoring in a more common form of pulmonary fibrosis in May, Bristol Myers Squibb’s lysophosphatidic acid receptor 1 (LPA1) antagonist has turned out positive results in a rarer incarnation of the disease. The clinical win ups the pressure on a pair of entrenched blockbusters in interstitial lung disease—Roche’s Esbriet and Boehringer Ingelheim’s Ofev.

As Novartis looks to sell off its eye disease unit, a geographic atrophy (GA) program is being discontinued on weak data, shutting down a pipeline of milestone payments related to the 2021 acquisition of Gyroscope Therapeutics.

Merck & Co. has unwrapped a fresh set of clinical data on sotatercept, providing further evidence of the safety and efficacy of the cardiovascular drug candidate ahead of a FDA ruling on whether to approve the jewel of the $11.5 billion Acceleron Pharma buyout.

Patients taking Crinetics’ rare growth disease drug were able to shift to the oral medicine from their standard of care injections while maintaining control of a key biomarker and symptoms during a late stage study.

Researchers have used stem cells to develop new human embryolike structures that model the earliest stages of fetal development so realistically that they even secrete hormones that can turn a lab pregnancy test positive.

Though Asensus Surgical has already gathered approvals for its robotic and artificial intelligence tools, the company isn’t resting. It’s signed up for an AI collaboration with Nvidia to continue developing its real-time vision features.

ILiAD Biotechnologies says it hit a homer in a whooping cough vaccine challenge trial. The biotech linked its nasal vaccine to protection against colonization by the pathogen, causing the phase 2b study to meet its primary endpoint in the per-protocol population.

Digital pathology player Paige has enlisted Microsoft to help construct what it claims will become the “world’s largest” artificial intelligence model built upon countless images of cancer biopsies.

Boston Scientific has obtained an FDA green light for the latest version of its Watchman heart implant, designed to help lower the risk of stroke in patients with atrial fibrillation.

Earlier this year, Philips set aside 575 million euros ($615 million) to prepare for a settlement over one set of complaints filed in the massive U.S. class-action lawsuit over the company’s ongoing recall of millions of CPAP and BiPAP machines, ventilators and other respiratory devices.